公开(公告)号：US12162878B2

公开(公告)日：2024-12-10

申请号：US17160302

申请日：2021-01-27

Applicant: HINOVA PHARMACEUTICALS INC.

Inventor： Lei Fan ,  Fei Wang ,  Xiaoquan Wu ,  Kexin Xu ,  Ke Chen ,  Tongchuan Luo ,  Shaohua Zhang ,  Yongxu Huo ,  Zhilin Tu ,  Xinghai Li ,  Yuanwei Chen

IPC: C07D471/04 ,  A61K45/06 ,  C07D519/00

Abstract: The compound of formula (I) has a good inhibitory effect on the proliferation of human prostate cancer cells CWR22RV1 and breast cancer cells; and combined use of the compound with an androgen receptor inhibitor HC-1119 significantly enhances the inhibitory effect on prostate cancer cells, and the inhibitory effect increases with increased concentration. The compound of formula (I) can not only be used independently to prepare an antineoplastic agent but can also be used in combination with other agents having antineoplastic effects, such as an androgen receptor inhibitor, or other targeting drugs etc., to prepare an antineoplastic agent having stronger therapeutic effects, especially an agent for treating prostate cancer and breast cancer.

公开(公告)号：US11572371B2

公开(公告)日：2023-02-07

申请号：US16647837

申请日：2018-09-14

Applicant: HINOVA PHARMACEUTICALS INC.

Inventor： Lei Fan ,  Kexin Xu ,  Ke Chen ,  Fei Wang ,  Xiaoquan Wu ,  Tongchuan Luo ,  Shaohua Zhang ,  Xinghai Li ,  Yuanwei Chen

IPC: C07D495/14 ,  A61P35/00

Abstract: Disclosed is a BRD4 inhibitor as shown in formula I, belonging to the field of compound drugs. The compound provided has a good inhibitory effect on prostate cancer cell proliferation, and can be used for preparing a drug combatting tumors, autoimmune or inflammatory diseases and viral infection, and in particular an anti-prostate cancer drug.